Skip to content

MDMA-Enhanced Exposure Therapy Reverses PTSD-Like Features In a Learned Helplessness Mouse Model

Orr Shahar, Perettz Golding, Masha Chaykin, May Ben Ari, Alexander Botvinnik, Tzuri Lifschytz, Bernard Lerer

bioRxiv (Cold Spring Harbor Laboratory) August 12, 2026 preprint DOI: 10.64898/2026.08.06.743271 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical study
Population Mice in a learned helplessness paradigm
Intervention MDMA
Topics MDMA PTSD
Key points MDMA combined with exposure to a traumatic cue produced rapid and sustained recovery in trauma-susceptible mice, with significant treatment- and time-dependent effects on avoidance behavior and dose-dependent effects on anxiety- and depression-related measures.

Abstract

Abstract Post-traumatic stress disorder (PTSD) is a highly prevalent, debilitating psychiatric condition. Existing treatments are ineffective for many patients. 3,4- methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has demonstrated substantial clinical efficacy but relies on prolonged, resource-intensive therapeutic protocols that limit scalability and accessibility. Here, we investigated whether combining MDMA with exposure-based intervention could enhance therapeutic efficiency in a preclinical model of PTSD-like behavior. Using a learned helplessness paradigm in mice, we identified trauma-susceptible individuals based on persistent escape failures following inescapable stress. Traumatised mice subsequently received brief treatment regimens consisting of MDMA or saline vehicle administered with or without exposure to the traumatic cue. Behavioral outcomes were tracked longitudinally using active avoidance performance as the primary endpoint, complemented by assays of anxiety- like, depressive-like, cognitive, and social behaviors. MDMA treatment markedly reduced trauma-associated behavioral deficits. MDMA combined with exposure produced rapid and sustained recovery compared to control conditions. Statistical analyses revealed significant treatment- and time-dependent effects on avoidance behavior, indicating accelerated resilience acquisition in MDMA-treated groups. Additional behavioral assays demonstrated dose-dependent effects of MDMA on anxiety- and depression-related measures. Together, these findings provide proof-of-principle that pharmacological modulation with MDMA can enhance exposure-driven behavioral recovery, supporting a strategy to integrate MDMA into more efficient and accessible PTSD treatment frameworks. This work establishes a preclinical foundation for clinical studies aimed at optimizing MDMA-assisted interventions to improve scalability and patient access.